Home > Back to Publisher > Report Information

Positron Emission Tomography (PET) Markets

TriMark Publications
July 1, 2011
225 Pages - SKU: TRI6444517

Abstract Table of Contents Related Reports

Positron Emission Tomography (PET) Markets

The medical imaging segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the computer and digital information technology segment. Continuous improvements in technology are resulting in a growing number of new imaging tests that combine high levels of accuracy with rapid, easy-to-use product formats. Part of that medical imaging improvement is coming from positron emission tomography (PET). PET is a scanning technique used in combination with small amounts of radio-labeled compounds to visualize the anatomy and function of the brain. The purpose of this TriMark Publications report is to describe the specific market segment of the diagnostics medical imaging market called PET scanning. This sector includes all of the generally accepted imaging activities that are currently used in PET, including equipment for PET, PET/CT, SPECT and the use of radiopharmaceuticals for imaging. It examines these clinical measurement devices and their reagents and supplies as used in hospitals and clinics. It also reviews associated clinical market segments in which PET scanning has taken a prominent role including cancer treatment, cardiology, and neurology imaging markets.

1. Overview: 1.1 Scope of This Report; 1.2 Methodology; 1.3 Executive Summary
2. PET Technology: An Overview: 2.1 History and Development of PET; 2.2 PET's Comparison with Other Conventional Imaging Procedures; 2.3 Trends in PET Instrumentation; 2.4 Cost Considerations in PET Scanners; 2.5 Economics of Hybrid Systems
3. PET Applications: An Overview: 3.1 Applications of PET and PET/CT in Oncology; 3.2 Applications of PET in Cardiology; 3.3 Application of PET in Neurology
4. PET Radioisotopes and Radiopharmaceuticals: 4.1 Types of Radiopharmaceuticals
5. Market Analysis: 5.1 Global Market for Medical Imaging Modalities; 5.2 PET and PET/CT Market; 5.3 Imaging Markets in Cardiology; 5.4 Nuclear Medicine
6. Company Profiles: 6.1 Actinium Pharmaceuticals, Inc.; 6.2 Advanced Medical Isotope Corporation; 6.3 Bio-Nucleonics; 6.4 Bracco Diagnostics, Inc.; 6.5 Covidien, PLC; 6.6 DRAXIMAGE, Inc.; 6.7 FluoroPharma, Inc.; 6.8 GE Healthcare; 6.9 Lantheus Medical Imaging, Inc.; 6.10 MIM Software Inc.; 6.11 Neusoft Medical Systems Co., Ltd.; 6.12 Nordion Inc.; 6.13 Numa, Inc.; 6.14 Philips Healthcare; 6.15 Positron Corporation; 6.16 Siemens Healthcare; 6.17 Thinking Systems Corporation
INDEX OF FIGURES: Figure 2.1: Illustration of the SMART Scanner; Figure 2.2: Illustrations of PET, CT and Fused PET/CT Scans; Figure 2.3: Collision of a Positron and Electron and the Creation of Two Resultant Gamma Rays; Figure 2.4: Discharge of Two Gamma Rays at 180 Degrees; Figure 2.5: A Sinogram with Coincidence Lines; Figure 2.6: PET Images Viewed in Axial, Coronal and Sagittal Planes; Figure 2.7: Block Diagram of PET Scanner; Figure 2.8: Principles of Operation of a Combined PET/CT Scanner; Figure 2.9: Two Scanners Mounted Back-to-Back for Sequential Acquisition; Figure 2.10: Full Integration of a Whole-Body PET/MRI System; Figure 3.1: Projection for Global Cancer Deaths, 2010-2030; Figure 3.2: Projected Cost of Cardiovascular Disease, 2010-2030; Figure 3.3: CVD: The Single Largest Killer in Adults; Figure 3.4: Prevalence of CVD in Four of the Ethnic Groups in the U.S.; Figure 3.5: Percentage Breakdown of Deaths from CVD in the U.S.; Figure 3.6: Costs of Major CVD Types in the U.S.; Figure 3.7: Increasing Number of Heart Failures in Europe, 2010-2020; Figure 3.8: CVD in Middle Income Countries; Figure 3.9: CVD in Developed Countries; Figure 5.1: Global Market for Medical Imaging Equipment by Geography, 2010; Figure 5.2: Global Medical Imaging Market Share by Modality, 2010; Figure 5.3: Global Cancer Cases, 2009-2020; Figure 5.4: U.S. Spending on Cancer, 2010-2020; Figure 5.5: Spending on Cancer in U.K., 2010-2020; Figure 5.6: Percent Comparison of Spending on Cancer, 2010; Figure 5.7: Volume Distribution in Cancer Imaging in the U.S.; Figure 5.8: Distribution of Outpatient Cancer Services in the U.S.; Figure 5.9: Global Market for Diagnostic Imaging Equipment for Oncology, 2010-2017; Figure 5.10: PET/CT's Share in Oncology Imaging Market, 2010-2017; Figure 5.11: Percent PET/CT Imaging by Cancer Type; Figure 5.12: Percent Share of Oncology, Cardiology and Neurology in PET/CT Scanning; Figure 5.13: Nuclear Cardiology Procedures for 100,000 of Population per Year for Developing vs. Developed Countries; Figure 5.14: Future of Nuclear Cardiology in 2014; Figure 5.15: Approximate Use of Cardiac Diagnostic Testing, U.S.; Figure 5.16: Utilization of Nuclear Cardiology in Developed Countries; Figure 5.17: Utilization of Nuclear Cardiology in Latin America; Figure 5.18: Utilization of Nuclear Cardiology Procedures in Asia/Oceania; Figure 5.19: Utilization of Nuclear Cardiology in Africa; Figure 5.20: Global Market for PET Services, 2010-2017; Figure 5.21: Projected Market Share of PET and SPECT in 2020; Figure 5.22: Growth Rate for SPECT and PET, 2011-2014; Figure 5.23: Number of Cameras: SPECT Switching to PET, 2011-2014; Figure 5.24: Top Ten Body Sites of Cancer for Men in the U.S.; Figure 5.25: Top Ten Body Sites of Cancer in U.S. Women; Figure 5.26: U.S. PET and PET/CT Patient Studies in Oncology, 2001-2008; Figure 5.27: U.S. PET and PET/CT Patient Studies in Cardiology, 2001-2008; Figure 5.28: U.S. PET and PET/CT Patient Studies in Neurology, 2001-2008; Figure 5.29: PET-Only Sites/Studies vs. PET/CT Sites/Studies; Figure 5.30: Trends in PET Procedure Volume in Finger Lakes Region, 2003-2009; Figure 5.31: U.S. PET Utilization by Body Site, 2009; Figure 5.32: U.S. PET Utilization Rate, 2003-2009; Figure 5.33: Approximate U.S. Sales of SPECT & SPECT/CT and PET & PET/CT, 2005-2009; Figure 5.34: Cardiac PET HOPPS payments, 2008-2011; Figure 5.35: U.S. Market for PET, 2010-2017; Figure 5.36: Percent Self-Reported Heart Disease By Age Group; Figure 5.37: Installed Units of PET in E.U, 2002-2013; Figure 5.38: Installed Units of PET/CT in E.U., 2002-2013; Figure 5.39: Growth of PET and PET/CT Examinations in E.U., 2002-2013; Figure 5.40: Location of PET Centers in Europe; Figure 5.42: PET Studies per Million Populations in Europe; Figure 5.41: Evolution of Cyclotron in Europe; Figure 5.43: Location of PET Cameras in Europe; Figure 5.44: Growth of Cyclotron Units in Europe, 2000-2010; Figure 5.45: European Nuclear Imaging Market Share by Geography, 2010; Figure 5.46: European Market for PET/CT, 2010-2017; Figure 5.47: Nuclear Imaging Market in Germany, 2010-2017; Figure 5.48: Nuclear Imaging System Market in France, 2010-2017; Figure 5.49: Nuclear Imaging System Market in U.K., 2010-2017; Figure 5.50: Nuclear Imaging System Market in Italy, 2010-2017; Figure 5.51: Number of Installed Bases in Nuclear Medicine in India; Figure 5.52: Nuclear Medicine Equipment Market in India; Figure 5.53: Indian Nuclear Medicine Equipment Market by Application; Figure 5.54: Global Demand Trend for Mo-99/Tc-99m; Figure 5.55: Global Market for Mo-99 by Geography/Country, 2009; Figure 5.56: Global Demand for Tc-99m (48 Million Doses/Year), 2009; Figure 5.57: Composition of Nuclear Medicine Procedures Utilizing Tc-99m; Figure 5.58: Global Demand for Mo-99 and Tc-99; Figure 5.59: U.S. FDG Sales, 2010-2017; Figure 5.60: U.S. Sales of Diagnostic Radiopharmaceuticals, 2007-2014; Figure 5.61: U.S. PET Procedure Volume Increase, 2007-2015; Figure 5.62: U.S. Sales of Fluorodeoxyglucose (FDG), 2007-2015; Figure 5.63: U.S. Export Share in Radioisotopes by Major Markets, 2007; Figure App. 2.1: Number of Global Nuclear Medicine Procedures Using for 99mTC/99Mo, 1990-2020; Figure App. 2.2: Growth of 99Mo Requirements, 1990-2020; Figure App. 2.7: Quantity of 99Mo Delivered to End-Users by Geography, 2007; Figure App. 2.8: Regional Shares of Reactor Production of 99Mo, 2007; Figure App. 2.9: Regional Shares of Reactor Production and Requirements of 99Mo, 2007; Figure App. 2.10: Regional Shares of Reactor Production and Requirements of 99Mo, 2007; Figure App. 5.1: Types of Nuclear Medicine Procedures that Can be Done Using Tc-99m; Figure App. 5.2: The basic linear supply chain for Tc-99m; Figure App. 5.3: North American Supply Chain for Tc-99m; Figure App. 5.4: Global Supply Chains for Tc-99m; Figure App. 5.5: Global Market Share by Reactor for Tc-99m; Figure App. 6.1: Growth in Allowed Services and Allowed Charges for Advanced Imaging Paid Under the MPFS, 1995 to 2005; Figure App. 6.2: Percentage of Total Growth in Allowed Services by Imaging Modality, 1995 to 2005; Figure App. 6.3: Percentage of Total Growth in Allowed Charges by Imaging Modality, 1995 to 2005; Figure App. 6.4: Growth in Advanced Imaging Utilization Rates, 1995 to 2005
INDEX OF TABLES: Table 2.1: Comparison of PET with Other Imaging Modalities; Table 2.3: Average Adult PET and PET/CT Scan Times; Table 2.4: Applications of PET in Oncology; Table 3.1: Applications of PET in Cardiology; Table 3.2: Characteristics of SPECT vs. PET in Cardiac Imaging; Table 3.3: List of Common PET Tracers Used in the Evaluation of Neurological Disorders; Table 4.1: Common PET Radioisotopes; Table 4.2: Examples of PET Radiopharmaceuticals; Table 4.3: Estimated Radiation Dose with Intravenous Administration of FDG in a 70-kg Patient; Table 4.4: PET Radiopharmaceuticals: Their Applications, Mechanisms of Uptake and Localizations; Table 4.5: FDA-Approved Radiopharmaceuticals as of August 3, 2010; Table 5.1: U.S. PET Locations and Exams; Table 5.2: Utilization by Payment Type in Finger Lake Region, 2009; Table 5.3: Effect of Coverage Changes on Oncologic Uses of FDG PET; Table 5.4: Volume Outlook for Outpatient Imaging, 2005-2015; Table 5.5: Medicare Reimbursement for PET Procedures; Table 5.6: Publicly Funded PET Scanners in Canada, 2009; Table 5.7: Funding for PET Scans (Period prior to October 1, 2009); Table 5.8: Alberta Indications; Table 5.9: Estimated Ontario New Cancer Cases, 2009; Table 5.10: Publicly Funded PET Scanners in Ontario 2009; Table 5.11: Approved International Indications for Clinical Use of 18F-FDG; Table 5.12: Availability of Publicly Funded Clinical PET Scanning in Canada; Table 5.13: European PET, PET/CT, PET/NM Installations; Table 5.14: Typical Radiation Doses; Table 5.15: PET Scanning Facilities in Europe; Table 5.16: PET Scanning Facilities in England; Table 5.17: Typical Radiation Doses; Table 5.18: Capital Costs for a PET Center with a Distant Supply of Tracer; Table 5.19: Staff Costs per Annum for Imaging with a Distant Supply of Tracer; Table 5.20: Fixed Costs per Annum for Imaging with a Distant Supply of Tracer; Table 5.21: Variable Costs per Annum for Imaging with a Distant Supply of Tracer; Table 5.22: Total Capital Scanning Costs for Imaging and Radiotracer Production Facility; Table 5.23: Capital Costs for Full Production of Radiotracer within an Imaging and Full Production of Tracer Facility; Table 5.24: Staff Costs per Annum for an Imaging and Full Production of Tracer Facility; Table 5.25: Staff Costs for the Cyclotron and Radiochemistry Within an Imaging and Full Production of Tracer Unit; Table 5.26: Fixed Radiotracer Production Costs; Table 5.27: Variable Scanning Costs; Table 5.28: Radiotracer Production Variable Costs; Table 5.29: Medical Cyclotrons in India; Table 5.30: PET/CT Scanner Profile in India; Table 5.31: PET/CT Scanners by Number of Slices in India; Table 5.32: Major current 99Mo producing reactors; Table 5.33: Characteristics of Positron Emitting Tracers Used in PET Perfusion Imaging; Table 5.34: Worldwide Production Capacity of 99Mo, 2009; Table 5.35: Small Scale Production of 99Mo, 2010; Table 5.36: Nuclear Medicine Procedures that Use Tc-99m; Table 5.37: Radiopharmaceuticals of Clinical Use in Europe; Table 5.38: Useful Radionuclides for Molecular Imaging; Table 5.39: U.S. Shipments, Consumption and Trade of Radioisotopes; Table 5.40: U.S. Exports, Imports and Trade Balance by Selected Countries, 2003-2007; Table 5.41: U.S. Imports of Radioisotopes for Consumption, 2003-2007; Table 6.1: Actinium's Product Pipeline; Table App. 1.1: Global Reactor Landscape; Table App. 1.2: Global Share of Nuclear Medicine by Reactor, 2009; Table App. 2.1: Radionuclides for Which Supply is Believed to be in Jeopardy in 2010-2020; Table App. 3.1: Imaging Properties of PET Crystals; Table App. 3.2: Average adult PET and PET/CT Scan Times; Table App. 3.3: Common PET Radioisotopes; Table App.3.4: Examples of PET Radiopharmaceuticals; Table App. 4.1: Research Reactors Producing Radioisotopes; Table App. 4.2: Estimated Worldwide Value of Radioisotope Production; Table App. 6.1: Ten Most Frequently Billed Advanced Imaging Procedure Codes, 2005; Table App. 6.2: Growth in Allowed Charges for Advanced Imaging Under the MPFS by Year, 1995-2005; Table App. 6.3: CT Services Billed Under the MPFS by Provider Specialty, 1995-2005; Table App. 6.4: PET Services Billed Under the MPFS by Provider Specialty, 1995-2005

Positron Emission Tomography (PET) Markets

Share this report

Other tasks

Research Assistance

Related Markets

PET (Positron Emission Tomography) Reports

Free Alert Me service